Intragenic ERBB2 kinase mutations in tumours
Philip Stephens, Chris Hunter, Graham R. Bignell et al. · Nature · 2004
Cited by 799 works. doi:10.1038/431525b
Authors
- Philip Stephens
- Chris Hunter
- Graham R. Bignell
- Sarah Edkins
- Helen Ruth Davies
- Jon W. Teague
- Sarah O’Meara
- Raffaella Smith
- Andy Barthorpe
- Matthew J. Blow
- Lisa Brackenbury
- Adam P. Butler
- Oliver B. Clarke
- Jennifer Cole
- Ed Dicks
- Angus Dike
- Anja Drozd
- Ken Edwards
References
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- A census of human cancer genes
- Opportunities and challenges in the development of kinase inhibitor therapy for cancer
- The role of HER2/neu expression and trastuzumab in non-small cell lung cancer
- Toward Customized Trastuzumab in HER-2/neu-Overexpressing Non-Small-Cell Lung Cancers